Advertisement
UK markets closed

  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     

  • HANG SENG

    17,284.54
    +83.27 (+0.48%)
     

  • CRUDE OIL

    83.01
    +0.20 (+0.24%)
     

  • GOLD FUTURES

    2,344.20
    +5.80 (+0.25%)
     

  • DOW

    38,130.63
    -330.29 (-0.86%)
     

  • Bitcoin GBP

    51,662.56
    -61.14 (-0.12%)
     

  • CMC Crypto 200

    1,393.73
    +11.16 (+0.81%)
     

  • NASDAQ Composite

    15,616.42
    -96.33 (-0.61%)
     

  • UK FTSE All Share

    4,387.94
    +13.88 (+0.32%)
     
Stocks:

Trending tickers

Microsoft, Alphabet, Anglo American, IBM, Astrazeneca, Unilever and Sainsbury's

BUZZ-AstraZeneca: gains after dodging bullet on diabetes drug

Reuters - UK Focus

** Shares (Berlin: DI6.BE - news) up 1.5 pct as US FDA panel decides not to recommend any restrictions on prescribing its diabetes drug Onglyza, despite a risk of heart failure linked to the medicine

** A tougher stance could have jeopardised sales, but Deutsche Bank (Xetra: 514000 - news) analyst Richard Parkes says he is leaving unchanged his forecast for Onglyza sales of $776 mln in 2015 growing to $1.25 bln in 2018, or 5% of group sales

** Stock also supported by news that the experimental immune system-boosting drug tremelimumab has won "orphan" drug status in US for treating malignant mesothelioma, a rare type of cancer

(RM (LSE: RM.L - news) : ben.hirschler.thomsonreuters.com@reuters.net)